annb0t
Top 20
With its stock down 28% over the past three months, it is easy to disregard Neuren Pharmaceuticals (ASX:NEU). However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes, the company is worth looking at. Particularly, we will be paying attention to Neuren Pharmaceuticals' ROE today.
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investorsâ money. Put another...
>>> Read more: Neuren Pharmaceuticals Limited's (ASX:NEU) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investorsâ money. Put another...
>>> Read more: Neuren Pharmaceuticals Limited's (ASX:NEU) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
